Pathway Capital Management LP Takes $4.19 Million Position in Arcellx, Inc. $ACLX

Pathway Capital Management LP purchased a new position in shares of Arcellx, Inc. (NASDAQ:ACLX) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 51,051 shares of the company’s stock, valued at approximately $4,191,000. Arcellx comprises approximately 20.6% of Pathway Capital Management LP’s portfolio, making the stock its 2nd largest position. Pathway Capital Management LP owned about 0.09% of Arcellx at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of ACLX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Arcellx by 5.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,753 shares of the company’s stock valued at $1,893,000 after buying an additional 1,390 shares in the last quarter. Empowered Funds LLC acquired a new position in shares of Arcellx during the first quarter worth approximately $1,768,000. Intech Investment Management LLC increased its holdings in shares of Arcellx by 27.7% in the first quarter. Intech Investment Management LLC now owns 21,967 shares of the company’s stock valued at $1,441,000 after purchasing an additional 4,760 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in Arcellx by 15.8% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,129 shares of the company’s stock worth $140,000 after purchasing an additional 290 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC raised its position in Arcellx by 7.1% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 3,428 shares of the company’s stock worth $226,000 after purchasing an additional 228 shares during the last quarter. Institutional investors own 96.03% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently commented on ACLX. Cantor Fitzgerald reissued a “neutral” rating and issued a $88.00 target price on shares of Arcellx in a research note on Thursday, October 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arcellx in a report on Wednesday, January 21st. Needham & Company LLC reissued a “buy” rating and set a $105.00 price objective on shares of Arcellx in a report on Monday, December 8th. Guggenheim reaffirmed a “buy” rating on shares of Arcellx in a research note on Monday, November 24th. Finally, Wolfe Research began coverage on shares of Arcellx in a research report on Tuesday, November 18th. They set a “peer perform” rating for the company. Nine research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $112.22.

Arcellx Stock Performance

Shares of NASDAQ:ACLX opened at $69.47 on Tuesday. The company has a 50 day moving average price of $67.95 and a two-hundred day moving average price of $74.99. The company has a market capitalization of $4.02 billion, a PE ratio of -17.68 and a beta of 0.36. Arcellx, Inc. has a 52 week low of $47.86 and a 52 week high of $94.07.

Arcellx (NASDAQ:ACLX) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.96) by ($0.03). The firm had revenue of $4.95 million during the quarter, compared to analyst estimates of $11.24 million. Arcellx had a negative net margin of 607.01% and a negative return on equity of 51.13%. On average, sell-side analysts forecast that Arcellx, Inc. will post -1.58 earnings per share for the current year.

Insider Transactions at Arcellx

In other Arcellx news, insider Christopher Heery sold 5,882 shares of the firm’s stock in a transaction that occurred on Wednesday, January 14th. The shares were sold at an average price of $68.51, for a total transaction of $402,975.82. Following the sale, the insider directly owned 23,749 shares in the company, valued at approximately $1,627,043.99. This trade represents a 19.85% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Over the last three months, insiders sold 19,790 shares of company stock worth $1,314,077. 8.35% of the stock is currently owned by corporate insiders.

Arcellx Company Profile

Arcellx, Inc (NASDAQ: ACLX) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company’s proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers.

The company’s pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development.